Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
33
Recruiting, any sponsor type, condition "malaria"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed797
33 trials
Showing 1 to 25, recently updated first.
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community TransmissionPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT07246525 · 4,800 participants (planned) · Start Sep 22, 2026 · Primary completion Nov 15, 2029
Drug: dihydroartemisinin-piperaquine · For: Malaria
Sites: Kampala, Uganda
GlaxoSmithKlineGSK (GSK)
NCT07545681 · 70 participants (planned) · Start Oct 7, 2026 · Primary completion Oct 8, 2027
Drug: GSK3772701 600 mg; GSK3772701 900 mg and 3 more · For: Malaria, Falciparum
Sites: Lambaréné, Gabon; Kampala, Uganda
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06607003 · 300 participants (planned) · Start Nov 26, 2024 · Primary completion Nov 26, 2027
Drug: P. vivax challenge agent derived from PvHMB-CCE001 · For: Malaria
Sites: Bethesda, Maryland
- The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron DeficiencyPivotal-lookingRecruiting
Nicole StoffelAcademic, hospital or other
NCT06816524 · 324 participants (planned) · Start Mar 13, 2026 · Primary completion Dec 31, 2027
Drug: R21-Matrix/M Vaccine (malaria vaccine); Measles-Rubella vaccine · For: Iron Deficiencies
Sites: Msambweni, Kenya
- Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruiting
Sanaria Inc.Industry
NCT06862453 · 42 participants (planned) · Start Mar 12, 2026 · Primary completion Aug 30, 2027
Drug: PfSPZ-LARC2 Vaccine; PfSPZ Challenge (7G8) · For: Malaria Falciparum
Sites: Tübingen, Germany
- Focal Mass Drug Administration for the Prevention of Malaria in PregnancyPivotal-lookingRecruiting
University of North Carolina, Chapel HillAcademic, hospital or other
NCT07021430 · 300 participants (planned) · Start Apr 22, 2026 · Primary completion Sep 2028
Drug: Dihydroartemisinin Piperaquine · For: Malaria Prevention
Sites: Kasese, Uganda
- DON in Pediatric Cerebral MalariaPivotal-lookingRecruiting
Douglas Postels, MD, MSNot stated
NCT05478720 · 152 participants (planned) · Start Aug 16, 2022 · Primary completion Nov 30, 2028
Drug: 6-diazo-5-oxo-L-norleucine (DON); Placebo and 1 more · For: Malaria, Cerebral
Sites: Blantyre, Malawi · 2 sites in all
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07811908 · 120 participants (planned) · Start Feb 12, 2026 · Primary completion Feb 4, 2027
Drug: KAE609; SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 13 sites in all
- Southeast Asia Dose Optimization of TafenoquinePivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04704999 · 820 participants (planned) · Start Jul 22, 2024 · Primary completion Oct 4, 2027
Drug: Tafenoquine; Chloroquine and 3 more · For: Plasmodium Vivax Malaria
Sites: Siem Reap, Cambodia; Jayapura, Indonesia; Vientiane, Laos · 6 sites in all
- First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07646353 · 40 participants (planned) · Start Jul 27, 2026 · Primary completion Apr 10, 2028
Drug: GSK4425689A SC; GSK4425689A IV and 1 more · For: Malaria, Falciparum
Sites: Manchester, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT06666491 · 324 participants (planned) · Start Nov 13, 2024 · Primary completion May 14, 2027
Drug: Tafenoquine; Primaquine and 1 more · For: Malaria, Vivax
Sites: Ahmedabad, India; Bikaner, India; Kolkata, India · 5 sites in all
Medicines for Malaria VentureAcademic, hospital or other
NCT07758985 · 75 participants (planned) · Start Sep 14, 2026 · Primary completion Aug 2027
Drug: Cohort 1 low dose lotilaner with a high-fat meal; Cohort 2 high dose lotilaner in fasted state and 1 more · For: Malaria
Sites: Bamako, Mali
- Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)Recruiting
Clinton Health Access Initiative Inc.Academic, hospital or other
NCT07749911 · 20,000 participants (planned) · Start Jul 14, 2026 · Primary completion Jun 2027
Drug: R21/Matris-M Malaria vaccine · For: Malaria; PLASMODIUM FALCIPARUM MALARIA
Sites: Boromo, Burkina Faso; Houndé, Burkina Faso; Karangasso-Vigué, Burkina Faso · 21 sites in all
- PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliPivotal-lookingRecruiting
Sanaria Inc.Industry
NCT07675785 · 300 participants (planned) · Start Jul 20, 2026 · Primary completion Jul 15, 2028
Drug: PfSPZ-LARC2 Vaccine · For: Malaria (Plasmodium Falciparum)
Sites: Bamako, Mali
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT07708714 · 250 participants (planned) · Start May 13, 2026 · Primary completion Nov 30, 2030
Drug: hydroxycarbamide · For: Sickle Cell Disease; Sickle Cell Anemia in Children
Sites: Kampala, Uganda
- Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaPivotal-lookingRecruiting
Victoria Biomedical Research InstituteAcademic, hospital or other
NCT07559370 · 1,116 participants (planned) · Start Jan 20, 2026 · Primary completion Jun 30, 2027
Drug: Artemether lumefantrine tablets; Artemether Lumefantrine and Imatinib Mesylate · For: Malaria (Plasmodium Falciparum)
Sites: Kisumu, Kenya
Medicines for Malaria VentureAcademic, hospital or other
NCT07011511 · 72 participants (planned) · Start Jun 30, 2025 · Primary completion Dec 2, 2027
Drug: MMV055 Dose 1; MMV055 Dose 2 and 6 more · For: Malaria, Falciparum
Sites: Nottingham, United Kingdom
- FocaL Mass Drug Administration for Vivax Malaria EliminationPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT05690841 · 7,530 participants (planned) · Start Oct 14, 2024 · Primary completion May 1, 2027
Drug: Focal Mass Drug Administration (fMDA) · For: Plasmodium Vivax Malaria; Malaria
Sites: Iquitos, Peru
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsPivotal-lookingRecruiting
Sanaria Inc.Industry
NCT07385287 · 180 participants (planned) · Start May 4, 2026 · Primary completion Feb 2027
Drug: Genetically attenuated PfSPZ Vaccine · For: Malaria (Plasmodium Falciparum)
Sites: Ouagadougou, Burkina Faso
Curtin UniversityAcademic, hospital or other
NCT07052162 · 30 participants (planned) · Start Oct 20, 2025 · Primary completion Mar 2026
Drug: Single dose tafenoquine (10 mg/kg) given with water; Single dose tafenoquine (10 mg/kg) given with fat · For: Pharmacokinetics of Tafenoquine
Sites: Madang, Papua New Guinea
Menzies School of Health ResearchAcademic, hospital or other
NCT07468513 · 100 participants (planned) · Start May 17, 2024 · Primary completion Jun 30, 2028
Drug: Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days; Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). · For: Vivax Malaria; G6PD Deficiency
Sites: Manaus, Brazil; Arba Minch, Ethiopia; Alexishafen, Papua New Guinea · 4 sites in all
- Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella DiseaseRecruiting
International Vaccine InstituteAcademic, hospital or other
NCT07416461 · 10,000 participants (planned) · Start Oct 27, 2025 · Primary completion Feb 2027
Drug: R21/Matrix-M malaria vaccine · For: Invasive Non-Typhoidal Salmonella Disease; Malaria; Malaria Vaccine
Sites: Kinshasa, Democratic Republic of the Congo
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of GhanaPivotal-lookingRecruiting
Noguchi Memorial Institute for Medical ResearchAcademic, hospital or other
NCT07389057 · 9,000 participants (planned) · Start Nov 1, 2023 · Primary completion Nov 30, 2026
Drug: DHAP; Single low dose PQ · For: Malaria Asymptomatic Parasitaemia; Malaria Falciparum; Malaria Infection and 1 more
Sites: Accra, Ghana
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in AfricaPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT06967519 · 380 participants (planned) · Start Dec 18, 2025 · Primary completion Dec 2027
Drug: Artemether-lumefantrine (AL); artesunate-amodiaquine (AS-AQ) · For: Malaria; Hiv
Sites: Kampala, Uganda · 2 sites in all
- A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected ErythrocytesRecruiting
University of OxfordAcademic, hospital or other
NCT05071079 · 48 participants (planned) · Start May 23, 2022 · Primary completion Nov 2026
Drug: An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum; An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum and 2 more · For: Plasmodium Vivax Infection
Sites: Bangkok, Thailand
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.